BEAM-101, a genetically modified cell therapy for sickle cell disease (SCD) that’s being tested in clinical trials, has been…
Articles by Marisa Wexler, MS
An algorithm that grew out of a collaboration between different specialties at the Medical University of South Carolina (MUSC) may…
Bluebird Bio and Xcellbio have entered into an agreement to support the commercialization of Lyfgenia (lovotibeglogene autotemcel), Bluebird’s gene therapy…
This year, for the first time, two teenagers in Florence, South Carolina, are going to be able to go swimming…
This month, the University of Tennessee Health Science Center College of Nursing is hosting a conference that aims to educate…
Scientists have discovered more than a dozen genes that regulate the production of fetal hemoglobin in people of African descent,…
Undergoing a bone marrow transplant during adolescence may reduce the risk of stroke in people with sickle cell disease…
AÂ sickle cell disease (SCD) patient in Bahrain received the gene-editing therapy Casgevy (exagamglogene autotemcel), becoming the first patient…
Children’s Hospital Los Angeles (CHLA) is now offering Casgevy (exagamglogene autotemcel), an approved gene-editing therapy for sickle cell…
The Bill and Melinda Gates Foundation is investing up to $50 million in Tessera Therapeutics to support the development…